Big Books & Bold Ideas with Kerri Miller

Researchers are making progress on a COVID-19 vaccine, but the race isn’t over yet

Researchers are making progress on a COVID-19 vaccine, but the race isn’t over yet

A subject receives a shot
A subject receives a shot in the first-stage safety study clinical trial of a potential vaccine by Moderna for COVID-19 at the Kaiser Permanente Washington Health Research Institute in Seattle on March 16, 2020. According to results released on Tuesday, July 14, 2020, early-stage testing showed the first COVID-19 vaccine tested in the U.S. revved up people's immune systems the way scientists had hoped. The vaccine is made by the National Institutes of Health and Moderna Inc.
Ted S. Warren | AP Photo file

Initial results from three separate groups working on COVID-19 vaccines look promising, but that doesn’t mean doses will be available at a local pharmacy soon.

Even if a formula gets approved, being able to manufacture and distribute enough doses at a global scale will be challenging.

Getting community buy-in is another hurdle. Polling from May showed that roughly half of Americans would get a COVID-19 vaccine if it was available. A separate poll from June found that around 7 in 10 Americans were willing to get the vaccine.

On Wednesday at 9 a.m., two experts joined MPR News host Kerri Miller for a conversation about the race to develop a COVID-19 vaccine. 

Guests

To listen to the full conversation you can use the audio player above.


Subscribe to the MPR News with Kerri Miller podcast on: Apple Podcasts, Google Podcasts , Spotify or RSS